The Centers for Medicare & Medicaid Services today issued a proposed rule setting forth a bundled payment model for radiation oncology, which would be mandatory in certain areas of the country. Under the model, participants would receive a bundled payment for 90-day episodes of radiation therapy for 17 disease sites, including breast, lung, prostate, kidney and colorectal cancer. This bundled payment would be made instead of regular Medicare fee-for-service payments; providers would keep any savings if spending is less than the bundled payment, subject to quality and patient experience measures, but also would be responsible for any spending above the payment amount. In addition, the model is designed to be site-neutral — that is, the bundled payment amount is designed to be calculated similarly regardless of whether the provider is a physician, hospital outpatient department or non-hospital setting. CMS proposes to run the model for five years, beginning either Jan. 1 or April 1, 2020. The proposed rule is expected to be published in the Federal Register soon, and CMS will accept comment for 60 days after publication. 

Related News Articles

Headline
The Centers for Medicare & Medicaid Services Oct. 31 released its calendar year 2026 final rule for the physician fee schedule. As required by law,…
Headline
The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model…
Blog
Public
Rural hospital leaders from across the country came together to share strategies and insights for improving safety culture, governance and care…
Headline
The application deadline for the Rural Health Transformation Program is Nov. 5. The program will fund $50 billion to rural providers from fiscal year 2026 to…
Headline
The AHA has released a social media toolkit in advance of National Rural Health Day Nov. 20 that includes advocacy-focused posts for hospitals and health…
Headline
The Senate Committee on Health, Education, Labor and Pensions Oct. 23 held a hearing discussing the 340B Drug Pricing Program and its growth and impacts on…